NCT02514512Active, not recruiting
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
Phase I Feasibility Study of Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation and Radiofrequency Tracking
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
A research study into a new technology for adjustment of the radiotherapy beam to account for movement of lung tumours as the patient breathes during radiotherapy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 12 Jul 2015
- Start date
- 1 Sept 2015
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Royal North Shore Hospital
- Diseases
- Lung cancer
- NCT number
- NCT02514512
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Sept 2015 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous high-dose thoracic radiotherapy.
- Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators)
- Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, or concurrently with treatment
Other
- Less than two Calypso beacons implanted in the lung.
- Calypso beacons are spaced by greater than 9cm or less than 1cm.
- Calypso beacons are less than 19cm from outer chest wall
- Women who are pregnant or lactating.
- Unwilling or unable to give informed consent
- Unwilling or unable to complete quality of life questionnaires
Who the study is looking for
- Aged 18 or older
- Has provided written Informed Consent for participation in this trial and is willing to comply with the study
- Patients undergoing external beam radiotherapy at Northern Sydney Cancer Centre
- Histologically proven Stage I Non Small Cell Lung Cancer (NSCLC) oligometastatic lung metastases (3 or less). Histological diagnosis will be obtained if clinically indicated.
- MRI/4D-CT prior to insertion of Calypso beacons
- Patient must be able to have Varian Calypso beacons placed in the lung (if on anticoagulants, must be cleared by Local Medical Officer (LMO) or cardiologist).
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Body habitus enabling Calypso tracking (as per Calypso Determining a Patient's Localisation Designation \& Orientation before implantation)
- A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately.
- Tumour diameter ≤ = 5cm
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal North Shore Hospital Coordinator of this site? Confirm its status | St Leonards | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.